Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas [Phase 2]
This clinical trial update summarizes the MALIBU Phase 2 study evaluating the combination of ibrutinib and rituximab in untreated marginal z…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Acalabrutinib and Tafasitamab in MZL Patients [Phase 2]
A Phase 2 clinical trial is evaluating the combination of acalabrutinib and tafasitamab in patients with marginal zone lymphoma; the study i…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL [Phase 2]
A Phase 2 clinical trial is evaluating the combination of Orelabrutinib with a Hi-CVP regimen for previously untreated marginal zone lymphom…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL [Phase 2]
Phase 2 trial of MZL-IPI risk-adapted targeted therapy for untreated marginal zone lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma [Phase 2]
This entry describes a Phase 2 clinical trial of low-dose mosunetuzumab for indolent B-cell lymphomas, currently recruiting at the Universit…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating Rituximab plus Venetoclax as frontline therapy for marginal zone lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial update of BGB-21447, a Bcl-2 inhibitor developed by BeOne Medicines, evaluating safety and preliminary activity in mu…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL [Phase 2]
This record describes an ongoing Phase 2 clinical trial evaluating orelabrutinib in combination with rituximab, with or without lenalidomide…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL [Phase 2]
An exploratory Phase 2 clinical trial evaluating Orelabrutinib for early-stage, untreated marginal zone lymphoma is currently recruiting in …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma [Phase 2]
Phase 2 trial evaluating Orelabrutinib followed by response-adapted ultra-low-dose 4 Gy radiation as first-line therapy for mucosa-associate…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…